Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INMBearishM&Anews

High materiality8/10

Mentari's $200M private placement linked to InMed merger

Jul 22, 2026, 7:05 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Dilution from the private placement and merger may pressure INM shares; execution risk and timing uncertainty often cap upside until approval.

AI summary

What happened, with direct paths to the underlying reporting

Mentari Therapeutics announced a $200 million private placement that extends its cash runway into 2029 and funds two PACAP-targeted leads (MT-001 and MT-002). The financing is tied to the merger with InMed Pharmaceuticals, with completion expected to trigger a new combined company trading under Mentari on the Nasdaq, and about 601 million shares outstanding post-close.

Mentari Therapeutics raises $200M in private placement. Investors include Fairmount, Venrock, Blackstone, RTW.
The funding extends Mentari's cash runway into 2029 and funds MT-001/MT-002.
The private placement will close before the InMed merger and Initial Private Placement.
Post-merger, combined company to trade as Mentari on Nasdaq Capital.
Estimated shares outstanding after closing about 601.2 million.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Mentari's $200M private placement linked to InMed merger

InMed Pharmaceuticals Announces Merger with Mentari Therapeutics

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday